Your browser doesn't support javascript.
loading
Bioinformatics for precision medicine in oncology: principles and application to the SHIVA clinical trial.
Servant, Nicolas; Roméjon, Julien; Gestraud, Pierre; La Rosa, Philippe; Lucotte, Georges; Lair, Séverine; Bernard, Virginie; Zeitouni, Bruno; Coffin, Fanny; Jules-Clément, Gérôme; Yvon, Florent; Lermine, Alban; Poullet, Patrick; Liva, Stéphane; Pook, Stuart; Popova, Tatiana; Barette, Camille; Prud'homme, François; Dick, Jean-Gabriel; Kamal, Maud; Le Tourneau, Christophe; Barillot, Emmanuel; Hupé, Philippe.
Afiliación
  • Servant N; Institut Curie, Paris France ; INSERM U900, Paris France ; Mines ParisTech, Fontainebleau France.
  • Roméjon J; Institut Curie, Paris France ; INSERM U900, Paris France ; Mines ParisTech, Fontainebleau France.
  • Gestraud P; Institut Curie, Paris France ; INSERM U900, Paris France ; Mines ParisTech, Fontainebleau France.
  • La Rosa P; Institut Curie, Paris France ; INSERM U900, Paris France ; Mines ParisTech, Fontainebleau France.
  • Lucotte G; Institut Curie, Paris France ; INSERM U900, Paris France ; Mines ParisTech, Fontainebleau France.
  • Lair S; Institut Curie, Paris France ; INSERM U900, Paris France ; Mines ParisTech, Fontainebleau France.
  • Bernard V; INSERM U932, Paris France.
  • Zeitouni B; Institut Curie, Paris France ; INSERM U900, Paris France ; Mines ParisTech, Fontainebleau France.
  • Coffin F; Institut Curie, Paris France ; INSERM U900, Paris France ; Mines ParisTech, Fontainebleau France.
  • Jules-Clément G; Institut Curie, Paris France ; INSERM U900, Paris France ; Mines ParisTech, Fontainebleau France ; INSERM U932, Paris France.
  • Yvon F; Institut Curie, Paris France ; INSERM U900, Paris France ; Mines ParisTech, Fontainebleau France.
  • Lermine A; Institut Curie, Paris France ; INSERM U900, Paris France ; Mines ParisTech, Fontainebleau France.
  • Poullet P; Institut Curie, Paris France ; INSERM U900, Paris France ; Mines ParisTech, Fontainebleau France.
  • Liva S; Institut Curie, Paris France ; INSERM U900, Paris France ; Mines ParisTech, Fontainebleau France.
  • Pook S; Institut Curie, Paris France ; INSERM U900, Paris France ; Mines ParisTech, Fontainebleau France.
  • Popova T; Institut Curie, Paris France ; INSERM U830, Paris France.
  • Barette C; Institut Curie, Paris France ; INSERM U900, Paris France ; Mines ParisTech, Fontainebleau France ; Institut Curie, Informatic Department, Paris France.
  • Prud'homme F; Institut Curie, Paris France ; INSERM U900, Paris France ; Mines ParisTech, Fontainebleau France ; Institut Curie, Informatic Department, Paris France ; Institut Curie, Sequencing Facility ICGex, Paris France.
  • Dick JG; Institut Curie, Informatic Department, Paris France.
  • Kamal M; Institut Curie, Translational Research Department, Paris France.
  • Le Tourneau C; INSERM U900, Paris France ; Mines ParisTech, Fontainebleau France ; Department of Medical Oncology, Institut Curie, Paris France.
  • Barillot E; Institut Curie, Paris France ; INSERM U900, Paris France ; Mines ParisTech, Fontainebleau France.
  • Hupé P; Institut Curie, Paris France ; INSERM U900, Paris France ; Mines ParisTech, Fontainebleau France ; CNRS UMR144, Paris France.
Front Genet ; 5: 152, 2014.
Article en En | MEDLINE | ID: mdl-24910641
ABSTRACT
Precision medicine (PM) requires the delivery of individually adapted medical care based on the genetic characteristics of each patient and his/her tumor. The last decade witnessed the development of high-throughput technologies such as microarrays and next-generation sequencing which paved the way to PM in the field of oncology. While the cost of these technologies decreases, we are facing an exponential increase in the amount of data produced. Our ability to use this information in daily practice relies strongly on the availability of an efficient bioinformatics system that assists in the translation of knowledge from the bench towards molecular targeting and diagnosis. Clinical trials and routine diagnoses constitute different approaches, both requiring a strong bioinformatics environment capable of (i) warranting the integration and the traceability of data, (ii) ensuring the correct processing and analyses of genomic data, and (iii) applying well-defined and reproducible procedures for workflow management and decision-making. To address the issues, a seamless information system was developed at Institut Curie which facilitates the data integration and tracks in real-time the processing of individual samples. Moreover, computational pipelines were developed to identify reliably genomic alterations and mutations from the molecular profiles of each patient. After a rigorous quality control, a meaningful report is delivered to the clinicians and biologists for the therapeutic decision. The complete bioinformatics environment and the key points of its implementation are presented in the context of the SHIVA clinical trial, a multicentric randomized phase II trial comparing targeted therapy based on tumor molecular profiling versus conventional therapy in patients with refractory cancer. The numerous challenges faced in practice during the setting up and the conduct of this trial are discussed as an illustration of PM application.
Palabras clave

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Tipo de estudio: Clinical_trials / Prognostic_studies Idioma: En Revista: Front Genet Año: 2014 Tipo del documento: Article

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Tipo de estudio: Clinical_trials / Prognostic_studies Idioma: En Revista: Front Genet Año: 2014 Tipo del documento: Article